U.S. Plans FDA Presence In China Next Month
This article was originally published in PharmAsia News
The top U.S. health official says the FDA plans to locate personnel in China beginning in May, subject to approval by Chinese authorities. Health and Human Services Secretary Mike Leavitt said in an interview in Singapore the first U.S. FDA office in China will be headed by the current director of the HHS Asia and the Pacific office, Christopher Hickey. Hickey said the FDA is still awaiting final approval from China for an FDA office there. Leavitt said FDA presence would allow not only inspections, but an ability to build capacity and maintain relationships with China's regulators. (Click here for more
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.